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AbstrAct
Objective Extensive molecular heterogeneity 
of pancreatic ductal adenocarcinoma (PDA), few 
effective therapies and high mortality make this 
disease a prime model for advancing development 
of tailored therapies. The p16-cyclin D-cyclin-
dependent kinase 4/6-retinoblastoma (RB) protein 
(CDK4) pathway, regulator of cell proliferation, is 
deregulated in PDA. Our aim was to develop a novel 
personalised treatment strategy for PDA based on 
targeting CDK4.
Design Sensitivity to potent CDK4/6 inhibitor 
PD-0332991 (palbociclib) was correlated to protein 
and genomic data in 19 primary patient-derived 
PDA lines to identify biomarkers of response. In vivo 
efficacy of PD-0332991 and combination therapies 
was determined in subcutaneous, intrasplenic and 
orthotopic tumour models derived from genome-
sequenced patient specimens and genetically 
engineered model. Mechanistically, monotherapy 
and combination therapy were investigated in the 
context of tumour cell and extracellular matrix 
(ECM) signalling. Prognostic relevance of companion 
biomarker, RB protein, was evaluated and validated in 
independent PDA patient cohorts (>500 specimens).
results Subtype-specific in vivo efficacy of PD-
0332991-based therapy was for the first time observed 
at multiple stages of PDA progression: primary 
tumour growth, recurrence (second-line therapy) and 
metastatic setting and may potentially be guided 
by a simple biomarker (RB protein). PD-0332991 
significantly disrupted surrounding ECM organisation, 
leading to increased quiescence, apoptosis, improved 
chemosensitivity, decreased invasion, metastatic spread 
and PDA progression in vivo. RB protein is prevalent in 
primary operable and metastatic PDA and may present a 
promising predictive biomarker to guide this therapeutic 
approach.
conclusion This study demonstrates the promise of 
CDK4 inhibition in PDA over standard therapy when 
applied in a molecular subtype-specific context.
IntrODuctIOn
Pancreatic ductal adenocarcinoma (PDA) is a 
molecularly diverse disease, driven by aberra-
tions in at least 10 core signalling pathways.1–4 In 
addition to revealing new biological insight into 
the molecular pathogenesis of PDA, these studies 
have created significant opportunities to develop 
novel, tailored treatments, as we have recently 
shown.5 6 The standard of care chemotherapeutic 
gemcitabine (GEM),7 in combination with nanopar-
ticle albumin-bound paclitaxel (nab-paclitaxel),8 
or FOLFIRINOX (oxaliplatin, irinotecan, fluoro-
uracil and leucovorin)9 offers only modest increases 
in patient survival in unselected populations.10 
Selective measures to personalise treatment in this 
aggressive disease are therefore urgently required.
The p16-cyclin D-CDK4/6-retinoblastoma 
(RB) protein pathway (CDK4 pathway) promotes 
G1/S-phase transition and is one of the key signal-
ling pathways deregulated in PDA.1 2 11 Cyclin D 
complexes with cyclin-dependent kinases (CDKs) 
4 and 6, driving RB protein phosphorylation and 
G1 phase progression.
12 In cancer, CDK4 activity 
and subsequent uncontrolled proliferation can be 
enhanced by homozygous deletion of CDKN2A 
gene (which encodes p16INK4A protein), CDK4/6 
mutations and/or cyclin D1 (CCND1) overexpres-
sion or amplification.13
Discovery of cyclin D/CDK4 as an oncogene 
has fuelled development of small-molecule CDK 
inhibitors (CDKi). Selective CDK4/6i, including 
PD-0332991 (palbociclib), are showing great 
potential in the treatment of ER+/HER2– meta-
static breast cancer.14–16 Although no biomarker of 
treatment response has been found, a key require-
ment for sensitivity to CDK4/6i in breast cancer 
may be linked to ER– positivity and dependence of 
the ER+ subtype on cyclin D1 signalling, enhancing 
CDK4/6 activity to drive proliferation.12 17
In PDA, short-term antiproliferative activity of 
CDK4/6i has been described.18 Here, we investigated 
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the therapeutic efficacy of CDK4/6i and clinically applicable 
combinations with long-term follow-up in realistic advanced 
preclinical patient-derived and genetically engineered models of 
PDA. We reveal a new role of CDK4 inhibition in regulating 
primary tumour growth and stromal desmoplasia in several 
independent mouse models of RB-high PDA, impairing coloni-
sation of secondary sites (liver) and resistance to shear stress, 
frequently experienced by circulating tumour cells (CTCs), 
while delaying disease progression in metastatic RB-high PDA. 
Detailed analyses reveal a complex mechanism of action with 
PD-0332991 exerting dual effects on both tumour cells and the 
surrounding environment. Assessment of RB expression, candi-
date CDK4/6i companion biomarker, revealed high prevalence 
in primary operable and metastatic human PDA. Collectively, 
these preclinical findings may offer promising new opportunities 
in subtype-specific targeting of primary and metastatic PDA.
MethODs
Patient-derived models
Our Kinghorn Cancer Centre (TKCC) patient-derived xeno-
grafts (PDXs; n=45) and patient-derived cell lines (PDCLs; 
n=19) have previously been whole genome sequenced.1 PDCLs 
were confirmed by short tandem repeat (STR) profiling as 
unique ( cellbankaustralia. com). Culture conditions, fluorescent 
ubiquitination-based cell cycle indicator (FUCCI) and luciferase 
introduction into PDCLs and associated in vitro studies: cell 
cycle, migration, invasion, shear stress, contraction and apop-
tosis assays are detailed in online supplementary information 2.
Animal studies
Survival studies were performed by subcutaneously implanting 
early third-passage PDX pieces (~4 mm3) into immunocompro-
mised Balb/c-Fox1nuAusb (Nude) mice. PD-0332991, GEM and 
nab-Paclitaxel dosages were based on published studies,5 18 19 
with treatment schedules, response measurement and setup for 
intrasplenic and orthotopic studies detailed in online supple-
mentary information 2.
Patient materials and immunohistochemistry
Patient samples and data were acquired through the Austra-
lian Pancreatic Genome Initiative (APGI)/International Cancer 
Genome Consortium (ICGC) (n=200), New South Wales 
Pancreatic Cancer Network (NSWPCN; n=365) and the Royal 
North Shore Hospital metastatic cohort (RNSH; n=54), as 
described.1 5 20 Further cohort description and immunohisto-
chemical procedures are outlined in online supplementary infor-
mation 2.
significance of this study
What is already known on this subject?
 ► Despite significant recent efforts into developing novel therapeutics, chemotherapy remains the standard of care for patients with 
advanced pancreatic cancer, despite only modestly improving overall survival.
 ► We and others have previously shown that pancreatic cancer is a molecularly varied disease and requires development of personalised 
treatment strategies to improve survival rates.
 ► Pancreatic cancer harbours frequent deregulation of the p16-cyclin D-CDK4/6-retinoblastoma (RB) protein pathway (CDK4 pathway), 
which could be therapeutically exploited.
What are the new findings?
 ► Using a range of robust patient-derived xenograft and cell line models, as ‘avatars of matched patient pancreatic tumours’, we 
show exquisite sensitivity to CDK4/6 inhibitor combinations over standard therapy in subtypes of pancreatic cancer, associated with 
increased apoptosis, quiescence and reduced expression of markers associated with pancreatic stellate cell activity.
 ► PD-0332991 facilitates remodelling of the extracellular matrix (ECM) to improve therapeutic efficacy of gemcitabine (GEM) in a 
subtype-specific manner and at multiple stages of disease progression: primary tumour growth, recurrence (second-line therapy) and 
the metastatic setting and may potentially be guided by a simple, clinically applicable biomarker (RB protein).
 ► CDK4 inhibitor, PD-0332991 (palbociclib) hinders metastatic colonisation in the liver while sensitising cells to shear stress, commonly 
experienced by metastasising circulating tumour cells, an additional way in which CDK4 inhibition can directly impinge on metastasis 
in RB-high pancreatic ductal adenocarcinoma (PDA).
 ► RB protein expression was identified as an independent prognostic factor for patient survival in two independent patient cohorts of 
pancreatic cancer and can be detected in a significant proportion of metastatic cases (67%). RB expression correlated between primary 
and matched metastatic human tissue.
 ► CDK4 pathway inhibition alone or in combination with chemotherapy leads to multifaceted global inhibitory effects on tumour cells at 
different stages of PDA progression and reduction in key components within the tumour microenvironment (ECM), which collectively 
drive cancer cell proliferation, invasion and chemoresistance.
how might it impact on clinical practice in the foreseeable future?
 ► Our findings, together with the recent clinical evidence on the efficacy of PD-0332991 in the treatment of breast cancer, support the 
further clinical companion biomarker-driven development of PD-0332991 as pancreatic cancer therapy, particularly in combination with 
chemotherapeutic, GEM.
 ► The use of a tissue-based assay for RB expression could be adapted for clinical application in diagnostics. As high RB expression 
was detected in a significant proportion of patients with pancreatic cancer (~65%,~43% and 67% in cohorts of primary operable 
and metastatic PDA examined), it may enable stratification and enrichment for the potential responders to the CDK4/6 combination 
therapy.
 ► These findings are timely and may be complementary and of direct relevance to the current non-biomarker-driven clinical trials testing 
PD-0332991 in pancreatic and other solid cancers (NCT02501902, NCT03065062).
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statistics
Statistical analyses were performed using GraphPad Prism 
(V7.0.1, GraphPad, La Jolla, California, USA) and Statview 
(V5.0, SAS Institute Inc., Cary, NC, USA). Correlation anal-
yses were performed using Pearson correlation coefficient 
test. Comparison between clinicopathological correlates was 
performed using Fisher's exact test, Student's t-test and Χ2 test, 
where appropriate. Survival analyses were performed using the 
log-rank test. For multiple treatment group comparisons, signifi-
cance was determined by one-way analysis of variance, followed 
by Tukey post hoc multiple comparisons test where *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. Clinicopatho-
logical variables shown by univariate analysis to have p<0.25 
were entered into a Cox proportional hazards regression model 
for multivariate analysis. To assess the agreement of RB status 
between primary and metastatic PDAs, Cohen's Kappa and 95% 
CIs were reported.
results
PD-0332991 sensitivity of pancreatic cancer patient-derived 
cell lines (PDcls) correlates with high levels of total and 
phosphorylated rb protein
To systematically examine the efficacy of CDK4/6i PD-0332991 
in PDA, we determined its toxicity in 19 whole genome-se-
quenced5 primary PDCLs and compared these data with several 
clinically used chemotherapeutics (see online supplementary 
table 1). PDCLs exhibited a broad range of PD-0332991 sensi-
tivity (inhibitory concentration 50 (IC50) range 8 nM–35 µM), 
with a subset (26%) being highly sensitive (IC50 <1 µM). The 
‘Genomics of Drug Sensitivity in Cancer’ (Wellcome Trust) 
database analysis revealed an association between RB1 muta-
tions and pan-cancer PD-0332991 resistance (p=3.3×10–17, see 
online supplementary figure 1A). As RB1 mutations in pancreatic 
cancer are rare1 (1/19 PDCLs; see online supplementary table 1), 
we next correlated the baseline protein expression of key G1/S 
checkpoint components (see online supplementary figure 1B, 
supplementary table 2) with in vitro PD-0332991 response. Of 
note, total and phosphorylated RB (pRB; Ser780) levels were the 
most significant biomarkers predicting PD-0332991 sensitivity 
(figure 1A; r=−0.751; p=0.0002 and r=−0.728, p=0.0004, 
respectively), with no correlation between G1/S checkpoint 
mutations/expression and response to PD-0332991 or chemo-
therapeutics in pancreatic PDCLs (see online supplementary 
table 3, supplementary figures 1C–E).
Effective target modulation was confirmed in candidate 
RB-high PDCLs by western blotting for pRB post-PD-0332991 
treatment (TKCC-03/-05; figure 1B), with no effect in RB-neg-
ative PD-0332991-resistant TKCC-27 cells (figure 1B, right). 
Interestingly, in RB-high, p16-positive, CDK6-amplified TKCC-
26, pRB was reduced post-PD-0332991, suggesting that in PDA 
CDK6 amplification may support sensitivity to CDK4/6i, irre-
spective of p16 expression.
chemotherapeutic GeM synergises with PD-0332991 in rb-
high and cDK6-amplified pancreatic PDcls
Combining PD-0332991 with standard of care therapy in PDA, 
GEM,7 in PDCLs and primary murine PDA cells (figure 1C) 
from the genetically engineered Pdx1-Cre, LSL-KrasG12D/+, 
LSL-Trp53R172H/+ (KPC) model21 22 produced robust cell 
line-specific efficacy, with combination index analysis23 showing 
a synergistic interaction between GEM and PD-0332991 in 
RB-high PDCLs (TKCC-03,-05,-15,-17,-26; figure 1D) and 
antagonism in RB-low/negative PDCLs (TKCC-06,-16,-23 and 
-27) and KPC cells (figure 1E). The robustness of synergy was 
confirmed by examining GEM/PD-0332991 treatment with 25 
drug combinations tested on five PDCLs, with synergy repeat-
edly observed across variable drug ratios in RB-high and antag-
onism in RB-low/negative lines (figure 1D,E inset, see online 
supplementary figure 2).
PD-0332991-based monotherapy and combination therapy 
induce critical effects on rb-high tumour cells
To understand the cellular mechanism of anti-tumour activity 
of PD-0332991 and its synergy with GEM, we examined the 
effect of selected treatments on cell cycle and apoptosis in candi-
date RB-high/RB-negative PDCLs (figure 1F) transduced with 
FUCCI, a fluorescent, two-colour biosensor of cell cycle progres-
sion24 (see online supplementary figure 3). Biosensor function 
and target modulation were confirmed by live cell imaging of 
PD-0332991-treated FUCCI-PDCLs (see online supplementary 
figure 4), showing robust G0/G1 arrest specifically in RB-high 
TKCC-05, not in RB-negative TKCC-27 cells, confirmed by 
traditional analysis (see online supplementary figure 4E,F).
Next, PD-0332991 treatment of FUCCI-TKCC-05 signifi-
cantly induced apoptosis (4–10 days; p<0.0001 and p<0.01, 
respectively; figure 1G, see online supplementary figure 5). In 
agreement with published work,25 GEM stimulated apoptosis. 
Importantly, GEM/PD-0332991 combination significantly 
increased the apoptotic effect of each monotherapy (figure 1G, 
see online supplementary figure 5C,E,G), not observed in 
RB-negative TKCC-27 (figure 1H, see online supplementary 
figure 5D,F,H), supporting the potentially cytotoxic mechanism 
of action of PD-0332991 in selected cell types. For comparison 
purposes, combination of PD-0332991 and clinically used GEM/
nab-paclitaxel8 was found to significantly enhance apoptosis in 
RB-high TKCC-05 (compared with GEM/nab-paclitaxel; see 
online supplementary figure 5C), although GEM/PD-0332991 
effects appeared more robust (across early/late time points, 
figure 1G).
To examine quiescence-associated alterations in cell cycle 
dynamics, we used an established flow cytometric methodology26 
to analyse FUCCI and quantify G0 versus G1 accumulation post-
PD-0332991-based treatments (figure 1I). Both PD-0332991 
and GEM/PD-0332991 significantly increased the mKO2++ 
G0 quiescent fraction,
26 compared with GEM or vehicle specifi-
cally in the RB-high setting (figure 1J,K; see online supplemen-
tary figure 6). Cell cycle analysis of drug-treated apoptotic cells 
revealed most significant increases in the G0 fraction post-PD-
0332991-based therapy (see online supplementary figure 6E). 
Collectively, these findings provide evidence that activated apop-
tosis and G0 quiescence are key mechanisms behind the observed 
synergy between GEM and CDK4/6i in 2D.
cDK4/6 inhibition modulates the invasiveness of rb-high PDA 
cells and ecM organisation
A single study reported that following incubation with a high 
PD-0332991 concentration (5 µM), selected commercial PDA 
lines displayed increased migratory capacity.27 Because both 
3D topology and mechanical cues provided by the stroma can 
shape and drive invasive tumour behaviour,28 we examined the 
effect of CDK4/6 inhibition on the invasive potential of RB-high 
and RB-negative PDA cells using an established 3D organotypic 
model of invasion6 29 (figure 2A). In 3D, PD-0332991 or GEM 
individually significantly impaired invasion of RB-high TKCC-05 
cells, with PD-032291 treatment being more effective (figure 2B, 
left, middle). Moreover, GEM/PD-0332991 combination 
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Figure 1 PD-0332991 potentiates gemcitabine (GEM) lethality in stratified pancreatic cancer patient-derived cell lines (PDCLs) and leads to 
increased apoptosis and G0 cell cycle quiescence. (A) Correlation of PD-0332991 sensitivity and expression of (left) retinoblastoma (RB) or (right) 
phosphorylated RB (pRB) in 19 PDCLs (normalised to β-actin levels and to low-expressing TKCC-16; included on multiple gels to account for any 
intergel/transfer variability). For densitometry analysis of normalised protein expression and correlation summaries please refer to supplementary 
tables 2 and 3. (B) Expression of pRB in RB-high (TKCC-03, TKCC-05, TKCC-26) and RB-negative (TKCC-27) PDCLs 24 hours post-PD-0332991 
treatment (0.3 µM or 1 µM, respectively). (C) Western blot depicting negligible levels of pRB and RB proteins in pancreatic cancer cells isolated 
from the genetically engineered Pdx1-Cre; KrasLSL.G12D/+; p53R172H/+ (KPC) model of pancreatic cancer. Combination index (CI) of the GEM/PD-
0332991 combination when agents were combined at a fixed ratio derived from their respective inhibitory concentration 50 (IC50) values in (D) RB-
high and (E) RB-low/negative PDCLs. CI values determined at various effective doses (EDs) were calculated using CompuSyn program. CI >1 indicates 
antagonism, CI <1 synergy and CI=1 additive.23 Data are presented as mean± SEM; (n=4 independent experiments performed in triplicate). Inset: Heat 
maps showing viability and CI values of GEM/PD-0332991 combination in various ratios in candidate (D) RB-high (TKCC-03) and (E) RB-negative 
cells (TKCC-27; n=3 independent experiments performed in triplicate). (F) Fluorescent ubiquitination-based cell cycle indicator (FUCCI)-labelled 
TKCC-05 or TKCC-27 cells were treated with GEM (0.01 µM for both), PD-0332991 (0.3 µM or 1 µM, respectively) or combination and at selected time 
points (3–10 days) stained with Annexin-V-Cy5/4',6-diamidino-2-phenylindole (DAPI) and analysed using flow cytometry. Total apoptosis quantified 
across all examined time points and treatments for (G) RB-high TKCC-05 and (H) RB-negative TKCC-27 cells. (I) Representative TKCC-05-FUCCI cell 
cycle plots and gating strategy post-treatment (10 days) and control. Quantified cell cycle distribution across all examined treatments (10 days time 
point) in (J) RB-high and (K) RB-negative PDCLs. Inset: Illustration of FUCCI cell cycle oscillations. Data are shown as mean±SEM (n=4 independent 
experiments), with comparisons performed against relevant vehicle controls, unless specified. Significance was determined by one-way analysis of 
variance, followed by Tukey post hoc multiple comparisons test, where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. PDA, pancreatic ductal 
adenocarcinoma; PFA, paraformaldehyde.
Pancreas
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Figure 2 CDK4/6i inhibition impairs the invasive potential of retinoblastoma (RB)-high pancreatic ductal adenocarcinoma (PDA) cells and disrupts 
collagen matrix integrity. (A) Schematic representation of organotypic invasion assay with PDA cells. (B) Invasion of vehicle-treated and drug-
treated enhanced green fluorescent protein (eGFP)-luciferase-labelled TKCC-05 cells through 3D organotypic matrices over 21 days, indicated by 
green fluorescent protein (GFP) immunohistochemistry. (C) Quantification of cell invasion (100 µm–400 µm). (D) Invasion of vehicle-treated and PD-
0332991-treated Pdx1-Cre; KrasLSL.G12D/+; p53R172H/+ (KPC) cells through 3D organotypic matrices over 14 days, indicated by multi-cytokeratin 
staining and (E) quantified. (F) Representative images of Ki-67 staining as a marker of cell proliferation and quantification of the percentage TKCC-05 
cells positive for Ki-67 in organotypic matrices following therapeutic intervention with PD-0332991-based approaches. (G) Representative images 
of cleaved caspase-3 (CC3) staining as a marker of cell apoptosis and quantification of TKCC-05 cells positive for CC3 (ratio normalised to control) 
in organotypic matrices post-treatment. (H) Schematic of a contraction assay (top), representative images of telomerase-immortalised fibroblast 
(TIF)–collagen control matrices (bottom) and (I) quantification of matrix area ±PD-0332991 at endpoint (9 days). (J) Representative maximum 
intensity projections of second harmonic generation (SHG) signal and (K) quantification of SHG signal intensity at peak in TIF–collagen matrices after 
9 days of contraction ±PD-0332991. (L) Bright-field and polarised light imaging of Picro Sirius Red-stained TIF–collagen matrices±PD-0332991 and 
quantification of total collagen content measured as (M) the total signal intensity (bright-field) and (N) intensity of the signal acquired via polarised 
light. (O) Contribution and quantification of signal emitted from fibres with high, medium and low birefringence normalised to total signal acquired 
via polarised imaging of Picro Sirius Red-stained collagen matrices ±PD-0332991. Thick remodelled collagen fibres are highly birefringent (red-
orange), whereas less remodelled fibres have a lower birefringence (green). Data for organotypic and collagen contraction studies are presented 
as mean±SEM (n=3 independent experiments, performed in triplicate matrices per condition, per repeat). Significance was determined by one-way 
analysis of variance, followed by Tukey post hoc multiple comparisons test, where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Unless 
specifically indicated, significance is compared against vehicle. GEM, gemcitabine; PDCL, patient-derived cell line.
Pancreas
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was markedly superior to each monotherapy (figure 2B, C). 
PD-0332991 did not affect the invasive capacity of RB-negative 
KPC cells in 3D (Figure 2D, E). Further, the observed inhibitory 
effects on RB-high TKCC-05 invasion were accompanied by 
decreased proliferation and increased apoptosis in PD-0332991 
and GEM/PD-0332991-treated matrices (figure 2F-G, see online 
supplementary figure 7A,B). In contrast, PD-0332991 treat-
ment slightly increased proliferation of invaded KPC cells, not 
affecting apoptosis (see online supplementary figure 7C,D). In 
2D, GEM/PD-0332991 reduced migratory capacity of RB-high 
TKCC-05 cells (see online supplementary figure 8), although 
PD-0332991-mediated effects were more pronounced in 3D, 
highlighting potential intricacies of CDK4/6 targeting of tumour 
cells within a complex microenvironment.
Since extracellular matrix (ECM) deposition, fibrosis and 
signalling processes play a major role in regulating phenotype of 
pancreatic tumour cells and therapeutic response,6 30 we inves-
tigated the effect of CDK4/6i on ECM integrity using primary 
fibroblast-driven contraction assays,31 as recently achieved by 
our team (figure 2H).32 PD-0332991 significantly impaired 
the ability of fibroblasts to contract (figure 2I) and remodel 
fibrillar collagen, as shown by second harmonic generation 
(SHG) imaging (figure 2J-K; see online supplementary video 1), 
and bright-field/polarised light microscopy of Picro-Sirius Red 
staining (Figure 2L-O), indicating a significantly disorganised 
ECM network in PD-0332991-treated matrices. Impairment 
of matrix contraction was independent of changes in fibroblast 
proliferation (in 2D and 3D; see online supplementary figure 
9). As these experiments revealed a significant anti-invasive, 
antiproliferative and ECM-modulatory activity of PD-0332991 
in complex 3D settings, we therefore sought to assess whether 
PD-0332991 and combinations affect PDA progression and drug 
response in vivo.
cDK4/6i monotherapy and combination therapy significantly 
improve survival of mice engrafted with rb-high patient-
derived pancreatic tumours
Therapeutic responsiveness in our early-passage PDXs was 
determined by measuring tumour growth, with experimental 
design (Figure 3A, see online supplementary figure 10A) 
enabling assessment of initial therapeutic responsiveness, and 
longitudinal analysis, comparing intrinsically resistant tumours 
with those that acquire resistance over time, as previously 
described.5 33 34 Strikingly, subtype-specific in vivo efficacy was 
observed, with all three RB-high PDXs examined showing signif-
icant long-term inhibition of tumour growth and improvement 
in overall survival following PD-0332991 monotherapy or 
GEM/PD-0332991 treatment, compared with standard of care 
(GEM and GEM/nab-Paclitaxel; Figure 3B-D, see online supple-
mentary table 4A–C). Since GEM/nab-Paclitaxel was associated 
with cumulative intestinal toxicity when administered over 4–5 
treatment cycles, efficacy of targeted therapies was compared 
with GEM only in the GEM-sensitive TKCC-PDX-26. In addi-
tion to improving survival, we observed significantly improved 
relapse-free survival (defined in online supplementary figure 
10) following GEM/PD-0332991, compared with GEM (see 
online supplementary figure 10). In contrast, RB-negative 
TKCC-PDX-27, RB-low TKCC-PDX-16 and RB-negative 
KPC orthografts were resistant to PD-0332991-based therapy 
(Figure 3E–G, see online supplementary table 5A–C). ‘On-target’ 
modulation was confirmed by measuring inhibition of pRB and 
proliferation (Ki-67; see online supplementary figure 11A,B) in 
PD-0332991-treated RB-high PDX-05.
Analysis of PD-0332991 and GEM/PD-0332991-treated 
RB-high tumour remnants revealed significant, prolonged 
in vivo inhibition of proliferation and increased apoptosis 
(Figure 3H-K), also associated with decreased α-smooth muscle 
actin (SMA) expression (Figure 3L-M; see online supplemen-
tary figure 11C), a prototypical marker of activated pancreatic 
stellate cells (PSCs), which drive the extensive fibrosis typically 
observed in PDA.35 36 In PD-0332991-resistant tumours, only 
GEM/nab-Paclitaxel treatment showed any significant modula-
tory effects (see online supplementary figure 11D–F). In agree-
ment with immunohistochemistry (IHC) analyses, the significant 
tumour regression observed in RB-high and CDK6-amplified 
PDXs post-treatment (30-day time point; see online supplemen-
tary figure 11G) further supports the idea that in addition to its 
cytostatic activity, PD-0332991 may exert cytotoxic effects on 
specific PDA subtypes in vivo.
PD-0332991-based therapeutic interventions inhibit spread 
in the liver while sensitising rb-high tumour cells to shear 
stress and reducing cell attachment
Next, we performed intrasplenic injections of RB-high TKCC-
05-FUCCI cells in parallel with systemic PD-0332991 admin-
istration as a way of examining efficacy of PD-0332991-based 
therapies in limiting pancreatic cancer spread to distant sites 
(Figure 4A). Pathology analyses on serial sections of liver 
metastases (Figure 4B,C) confirmed that mice treated with 
PD-0332991 and GEM/PD-0332991 showed a marked reduc-
tion in metastatic spread compared with GEM/nab-Paclitaxel. 
FUCCI analyses of the same liver tissues further confirmed 
in vivo PD-0332991 activity and ability to effectively inhibit 
CDK4/6 in liver metastases (Figure 4D, E).
To further understand the observed PD-0332991-mediated 
reduction of liver colonisation, we examined viability (apoptosis) 
and cell attachment of RB-high and for comparison, RB-nega-
tive PDA cells after exposure to controlled shear stress (100 µL/s, 
maximum force of 1950 dyn/cm2, Figure 4F),6 37 which CTCs are 
exposed to in vivo. PD-0332991 significantly induced post-stress 
cellular apoptosis and decreased cell attachment onto a collagen 
matrix, specifically in RB-high tumour cells (Figure 4G-I, J-K). 
Collectively, these experiments suggest a direct role of CDK4/6 
targeting in sensitising CTCs already exposed to shear stress as 
a potential mechanism in which PD-0332991 may modulate 
metastasis in PDA.
PD-0332991-based therapies significantly improve survival 
and delay metastasis in metastatic rb-high PDA
To examine the effect of CDK4/6i on PDA tumour progression 
and metastasis, mice were orthotopically injected with lucifer-
ase-TKCC-05 tumours, imaged 1 week post-injection (see online 
supplementary figure 12A), randomised and treated with stan-
dard chemotherapies, PD-0332991 and PD-0332991-based 
combinations, until ethical endpoint (Figure 5, top).
Critically, PD-0332991-based regimens were significantly 
more effective than standard therapies (Figure 5A, bottom, 
see online supplementary table 6) in RB-high metastatic PDA, 
with GEM/PD-0332991 proving the best therapeutic approach 
(median survival=117 days, p=0.0001; vs GEM/nab-Pacli-
taxel median survival=69 days). In addition, metastasis-free 
survival, monitored by in vivo imaging system (IVIS; see online 
supplementary figure 12B–C), was significantly increased by 
PD-0332991-based treatments (see online supplementary figure 
13A, supplementary table 7). Given in vitro efficacy was observed 
when PD-0332991 was combined with GEM/nab-Paclitaxel (see 
group.bmj.com on November 16, 2017 - Published by http://gut.bmj.com/Downloaded from 
7Chou A, et al. Gut 2017;0:1–14. doi:10.1136/gutjnl-2017-315144
Figure 3 In vivo tailored response of pancreatic ductal adenocarcinoma (PDA) models to PD-0332991 and rationally designed treatment 
combinations. (A) Preclinical testing pipeline in subcutaneous models. Treatment commenced when tumours reached 150 mm3 (100%), where 
each mouse was randomised into outlined treatment groups: (a) gemcitabine (GEM) 120 mg/kg twice weekly intraperitoneally (IP) for 25 days, 
(b) PD-0332991 150 mg/kg daily gavage for 21 days, (c) GEM (120 mg/kg) twice weekly IP and PD-0332991 (150 mg/kg) daily gavage or (d) GEM 
(70 mg/kg) and nab-Paclitaxel (30 mg/kg) twice weekly IP for 25 days. In the combination arm, PD-0332991 was administered from week 2 for 21 
days, 24 hours post-chemotherapy. Treatment response was measured from initiation of therapy (at maximal tolerable dose), through to the time 
resistance developed (characterised by progressive tumour growth in the presence of drug), and was based on our published work, with a 14-day 
minimal recovery time before additional treatment cycles. Details on treatment administration are further outlined in supplementary information 
2. (B–D) Kaplan-Meier survival analyses of response to PD-0332991 and GEM/PD-0332991 in patient-derived xenografts (PDXs) stratified based 
on retinoblastoma (RB) status, presented as overall survival. (E–G) Overall survival of immunocompromised or syngeneic mice bearing the RB-
negative/low TKCC-PDX-27, PDX-16 and subcutaneous Pdx1-Cre; KrasLSL.G12D/+; p53R172H/+ (KPC) tumours, respectively, treated with CDK4/6i 
monotherapy and combination, compared with standard therapies for PDA. (H) Representative images of Ki-67 immunohistochemistry performed 
on PDX-03 and (I) analysed for RB-high PDXs post-treatment (collected at endpoint). (J) Representative images of cleaved caspase 3 (CC3) staining, 
marker of apoptosis, in PDX-03 and (K) quantified for RB-high PDXs. (L) Representative images of α-smooth muscle actin (SMA) stromal expression 
post-therapy and (M) staining quantified for RB-high PDXs across all treatment groups (n=6 mice per treatment group). Data are shown as 
mean ±SD. Significance was determined by one-way analysis of variance, followed by Tukey post hoc multiple comparisons test, where *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. Unless specifically indicated, significance is compared against vehicle.
Pancreas
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Figure 4 CDK4/6 inhibition decreases cell colonisation and improves chemotherapy response in metastatic sites and makes retinoblastoma (RB)-
high tumour cells more vulnerable to shear stress. (A) Schematic representation of intrasplenic injection of RB-high TKCC-05-fluorescent 
ubiquitination-based cell cycle indicator (FUCCI) cells and associated treatment timeline. (B) Representative images and (C) quantification of liver 
micrometastasis and total metastasis normalised to liver surface area in H&E serial sections. Arrows point to metastases in the liver tissue. Data 
are shown as mean±SD (n=4 mice per group and five serial sections per organ (50 µm step)). (D) Representative pictures of metastases identified via 
imaging of FUCCI signal and (E) quantified cell cycle distribution in liver metastases from the TKCC-05-FUCCI intrasplenic model at the experimental 
endpoint. (F) Schematic of the fluid shear stress assay, adapted from Barnes et al [37]. (G) Representative TKCC-05-FUCCI apoptosis plots and 
(H) quantification of total, early and late apoptosis in TKCC-05 cells±PD-0332991 (0.3 µM) 24 hours following shear stress. P0 represents cells not 
subjected to shear stress and P5 represents cells subjected to five consecutive exposures to shear stress. (I) Quantification of cell attachment onto 
the collagen matrix, following shear stress of RB-high TKCC-05 cells±PD-0332991 treatment, measured 24 hours post-seeding. Y-axis values (P5/
P0 ratios) are values for cells subjected to five exposures to shear stress divided by values for cells not exposed to shear stress. (J) Quantification of 
apoptosis in RB-negative TKCC-27 cells±PD-0332991 (1 µM) 24 hours following shear stress. (K) Quantification of cell attachment onto the collagen 
matrix, following shear stress of RB-negative TKCC-27 cells±PD-0332991 treatment. Data are shown as mean±SEM (n=3 biological repeats with two 
collagen-coated wells per condition). Significance was determined by one-way analysis of variance, followed by Tukey post hoc multiple comparisons 
test, where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. Unless specifically indicated, significance is compared against vehicle.  DAPI, 
4',6-diamidino-2-phenylindole; GEM, gemcitabine.
Pancreas
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Figure 5 CDK4/6i therapy induces in vivo quiescence at primary tumour site, impairs metastatic spread and improves gemcitabine (GEM) efficacy 
in a metastatic patient-derived retinoblastoma-positive model of pancreatic ductal adenocarcinoma (PDA). (A) Schematic illustrating in vivo testing 
in a metastatic patient-derived model (top). Briefly, 15 000 luciferase-labelled patient-derived cell lines (PDCLs) were injected into the pancreas of 
6–8-week-old Nod/Scid/IL-2Rγnull (NSG) mice. Mice were randomised into treatment groups at 1 week post-injection, with two additional treatment 
arms included, involving triple combination of GEM (70 mg/kg), nab-Paclitaxel (30 mg/kg) twice weekly intraperitoneally administered either 
concomitantly with PD-0332991 (100 mg/kg) gavage from week 2 on a 5 day ‘on’, 5 day ‘off’ schedule for 20 days or with PD-0332991 administered 
as maintenance therapy by daily gavage after completion of GEM/nab-Paclitaxel treatment. Tumour burden was monitored weekly by bioluminescent 
imaging until ethical endpoint. Kaplan-Meier survival analyses of PD-0332991 monotherapy, in combination with GEM (left) or triple combinations 
with GEM/nab-Paclitaxel (right), compared with GEM/nab-Paclitaxel. Log-rank analysis, *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. (B) 
Experimental setup for in vivo second-line therapeutic testing in metastatic PDA (top). In vivo efficacy of GEM/PD-0332991 combination following 
progression on GEM/nab-Paclitaxel (bottom). (C) Representative images of pancreas tumours (left) and associated liver metastases (right) from 
orthotopic fluorescent ubiquitination-based cell cycle indicator (FUCCI)-TKCC-05 tumours collected 50 days post-treatment with CDK4/6i-based 
treatment or standard therapy (GEM/nab-Paclitaxel). Vehicle controls were collected prior to the 50-day time point, as expected, due to a heavy 
tumour burden. Shown is representative nuclear staining (4',6-diamidino-2-phenylindole (DAPI), top), FUCCI (mKO2—red, mAG—green, overlay—
yellow, CD31—blue; middle) and H&E section (bottom). Quantified cell cycle distribution of (D) primary tumours and (E) liver metastases from 
examined treatment groups, with (F) no metastases detected in PD-0332991 and GEM/PD-0332991-treated animals. (G) Representative overlay 
of maximum intensity projections of second harmonic generation (SHG) signal and FUCCI with quantification of SHG signal intensity at peak in 
orthotopic FUCCI-TKCC-05 tumours collected post-treatment. (H) Representative polarised light images of tumour tissue and quantification of total 
birefringence signal (black) and contribution to signal emitted from collagen fibres with high (red), medium (yellow) and low (green) birefringence 
acquired via polarised light imaging (n=4 animals per treatment group were used for analysis in (D, E, F, G and H). Significance was determined by 
one-way analysis of variance, followed by Tukey post hoc multiple comparisons test, where *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
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online supplementary figure 5), we also examined this combi-
nation in vivo. While treatments were generally well tolerated 
in experimental animals, the two triple combinations examined 
using GEM/nab-Paclitaxel and PD-0332991 were associated 
with some toxicity, namely constipation, which was treated with 
paraffin oil and controlled by adjusting PD-0332991 dosage. 
Both regimens, involving concomitant PD-0332991 administra-
tion (concomitant) or aiming to assess the potential of CDK4/6i 
as maintenance therapy in between chemotherapy cycles 
(maintenance), demonstrated a significant therapeutic benefit 
over GEM/nab-Paclitaxel (Figure 5A, bottom right, see online 
supplementary tables 6 and 7), but were not superior to GEM/
PD-0332991.
Following initial treatment with GEM/nab-Paclitaxel, a 
short-term response was followed by progression, measured 
as increased bioluminescence signal (see online supplementary 
figure 12C). To examine the therapeutic potential of GEM/
PD-0332991 in slowing PDA progression in advanced disease 
settings, separate cohorts of relapsed animals were subsequently 
switched to GEM/PD-0332991 or as control, clinically used 
second-line therapy, capecitabine,38 39 with a superior thera-
peutic benefit measured with GEM/PD-0332991 (Figure 5B, 
see online supplementary tables 6 and 7). In concordance, 
analyses of orthotopic FUCCI-TKCC-05 tumours collected 
50 days post-treatment revealed marked quiescence at the 
primary site (pancreas tumour), regardless of proximity to 
vessels (Figure 5C-E, see online supplementary figure 13B–C), 
and no liver metastases in animals treated with PD-0332991 or 
GEM/PD-0332991 (Figure 5C,F). SHG imaging and polarised 
light microscopy of Picro-Sirius Red-stained TKCC-05-FUCCI 
tumours confirmed that PD-0332991-based therapy reduces 
fibrillar collagen organisation (Figure 5G-H; see online supple-
mentary figure 14A), leads to increased apoptosis and decreased 
expression of α-SMA in vivo (see online supplementary figure 
14B,C).
These data indicate that CDK4/6 inhibition significantly delays 
pancreatic tumour progression by directly targeting tumour 
cells (G0 quiescence, apoptosis) and critical components of the 
microenvironment that have been shown to regulate chemoresis-
tance (ie, decreased stromal activation, reduced fibrillar collagen 
organisation). As robust efficacy was observed in multiple, inde-
pendent models of RB-high PDA, RB-based stratification could 
potentially facilitate a more tailored treatment approach for 
CDK4-targeting therapy in pancreatic cancer.
nuclear rb is prevalent in primary operable and metastatic 
human PDA and has prognostic value
Next, we immunohistochemically examined the expression of 
RB in human PDA and whether its disruption has prognostic 
significance (Figure 6A). High RB expression was detected in 
64.5% of primary tumour specimens from the APGI/ICGC 
cohort1 (n=200) and correlated with significantly improved 
survival (Figure 6B-C, see online supplementary table 8) and 
lower tumour grade (see online supplementary table 9). Multi-
variate analysis using a Cox proportional hazards model demon-
strated RB loss as an independent poor prognostic factor for 
disease-specific survival (DSS) (HR 1.552, p=0.0148, table 1). 
In contrast, p16 expression, examined for comparison purposes, 
was not prognostic (see online supplementary figure 15A–D). 
Deregulation of RB signalling has been linked with improved 
chemoresponsiveness in breast cancer40; however when 
correlated, RB expression did not specifically associate with 
survival following adjuvant GEM (see online supplementary 
figure 15E,F). As expected, RB and p16 levels strongly correlated 
in the PDX (n=45) and patient tumours from which they were 
derived (p<0.001, see online supplementary table 10).
The potential prognostic value of RB was subsequently vali-
dated in an independent patient NSWPCN cohort20 (n=314), 
where similar relationships between RB expression and survival 
were apparent in univariate (Figure 6D-E, see online supple-
mentary table 8) and multivariate analyses (HR 1.364, p=0.02, 
table 1). As most patients present with advanced stage PDA, 
we also assessed RB status in metastatic disease (n=54; see 
online supplementary tables 11 and 12). RB protein was highly 
expressed in 67% of metastatic specimens. Concordance in RB 
expression between matched primary and metastatic tumours of 
PDA, available for 12 of the 54 metastatic samples, was observed 
in 11 cases (91.7%; Cohen’s Kappa score 0.75; Figure 6F-G) 
indicating the strength of the agreement as ‘good’.
Collectively, these data demonstrate that a significant propor-
tion of primary operable and metastatic PDA express high levels 
of the prognostically relevant RB. This druggable, constitutively 
active pathway may represent an attractive therapeutic target, 
with immunohistochemical analysis of RB as a potentially simple 
prognostic and predictive biomarker to guide this therapeutic 
approach.
DIscussIOn
Despite significant recent efforts into developing novel treat-
ment combinations,41 chemotherapy remains the standard of 
care for most patients with advanced pancreatic cancer, despite 
only modestly improving survival.8 With rapid implementation 
in the clinical management of specific breast cancers, CDK4/6i 
are increasingly being tested in other solid tumours.42 43 Here, 
we examined whether CDK4 pathway inhibition in combination 
with chemotherapy represented a viable therapeutic approach 
for pancreatic tumours characterised by G1/S checkpoint aberra-
tions, frequent in the molecular landscape of PDA.1 We demon-
strate potent efficacy of single agent and combination CDK4/6i 
therapy in subtypes of PDA characterised by high RB expression, 
significantly improving long-term survival while delaying the 
development of metastasis in robust in vivo models of PDA. We 
also reveal that the potent efficacy of CDK4/6i monotherapy and 
combination therapy occurs via a complex mechanism involving 
deregulation of tumour cell signalling and disruption of the 
surrounding ECM that collectively drive cancer cell prolifera-
tion, invasion and metastasis6 30 44 while revealing a new role 
of CDK4/6 inhibition in governing tolerance to shear stress, 
an often overlooked area of premetastatic niche formation for 
CTCs.45 46
A major area of active investigation is the identification of 
biomarkers of therapeutic response to CDK4 inhibition. In 
preclinical models of melanoma and glioblastoma, homozygous 
loss, methylation or mutation of CDKN2A gene were shown 
to associate with sensitivity to CDK4/6i,47 48 although in the 
clinic, CDK4/6i sensitivity may not be strictly defined by p16 
status.49 Here, we show that RB expression, but not G1/S check-
point mutations or p16 levels, may present a robust stratifying 
biomarker for PD-0332991-based therapy in advanced preclin-
ical models of PDA.
PD-0332991 has traditionally been thought to exert its 
anti-tumour effects by promoting cytostasis, also supported by 
limited data in PDA, whereby using 7-day assessment of prolif-
eration as a read-out of PD-0332991 activity, early efficacy has 
been measured in almost all PDA explants examined.18 Deeper 
exploration of the long-term responsiveness to PD-0332991 
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Figure 6 High retinoblastoma (RB) expression is prevalent in human pancreatic ductal adenocarcinoma (PDA) and is of prognostic relevance 
in independent cohorts of the disease. Examples of (A) (left) RB-negative primary tumour (0); (middle) weakly RB-positive tumour (1+) and 
(right) RB-high tumour (2+). Kaplan-Meier analyses of disease-specific survival based on RB immunohistochemistry in (B and C) the Australian 
Pancreatic Genome Initiative (APGI)/International Cancer Genome Consortium (ICGC) cohort and (D and E) the New South Wales Pancreatic Cancer 
Network (NSWPCN) patient cohort. Survival analyses were performed comparing (B and D) all three RB groups and (C and E) RB-high (2+) versus 
RB-low in both sets. p Values, log-rank. (F) Examples of (left) RB-high and (right) RB-low primary tumours and matched metastases. (G) The agreement 
of RB status between primary and metastatic tumours of PDA. The number of observed agreements is 11 (91.67% of the observation), with a Kappa 
score 0.75 (SE of Kappa 0.232, 95% CI 0.296 to 1.000), indicating the strength of agreement is ‘good’.
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table 1 Multivariate analysis of retinoblastoma (RB) and key factors 
associated with disease-specific survival in independent clinical cohorts 
of resected pancreatic ductal adenocarcinoma.
Variable
Australian Pancreatic Genome 
Initiative cohort (n=200)
new south Wales Pancreatic 
cancer network cohort 
(n=314)
hr 95% cI
p  
Value hr 95% cI
p  
Value
Gender
Female 1.15 0.899 to 1.471 0.2656
Male 1
R status
Clear 0.712 0.482 to 1.052 0.0882 0.635 0.492 to 0.821 0.0005
Involved 1 1
Differentiation
Well/
moderate
0.384 0.046 to 3.224 0.0022 0.802 0.607 to 1.060 0.1216
Poor/
undifferentiated
1 1
Perineural 
invasion
Absent 0.818 0.484 to 1.382 0.452 0.917 0.692 to 1.216 0.5467
Present 1 1
Tumour size
<20 mm 0.663 0.315 to 1.396 0.2795 0.563 0.413 to 0.769 0.0003
≥20 mm 1 1
Lymphovascular 
invasion
Absent 0.729 0.475 to 1.120 0.1496 0.864 0.669 to 1.117 0.2642
Present 1 1
Lymph node 
involvement
Absent 0.736 0.446 to 1.213 0.2287 0.735 0.564 to 0.956 0.0218
Present 1 1
AJCC stage32
Stage I/II 0.731 0.335 to 1.598 0.4325 0.425 0.228 to 0.790 0.0068
Stage III/IV 1 1
RB status
RB 0 or 1+ 1.552 1.090 to 2.210 0.0148 1.364 1.048 to 1.776 0.0209
RB 2+ 1 1
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and combination therapy, directly compared with standard of 
care treatments, in this study highlights the need for a person-
alised approach in the treatment of pancreatic cancer, where 
RB-high PDA tumours respond long term to PD-0332991-based 
therapy in vivo and RB-low/negative tumours do not. Moreover, 
building on recent studies in other cancers, which suggest a more 
complex mechanism of action for CDK4/6i, including inhibition 
of EMT signalling in breast cancer metastasis50 and improved 
anti-tumour immunity,51 our study provides additional new 
evidence that PD-0332991 displays multifaceted effects on 
tumour cells (quiescence, apoptosis), alters ECM organisation 
and reduces tolerance to shear stress (Figure 4), thereby having a 
global effect in this aggressive disease, not examined previously.
Using a combination of 2D, 3D in vitro and in vivo models, we 
specifically show that PD-0332991 significantly induces apop-
tosis in RB-high pancreatic tumour settings and also enhances 
the apoptotic effect of chemotherapeutic GEM, a well-toler-
ated and clinically used agent in PDA (figures 1-3). Monitoring 
the onset of liver metastasis in vivo revealed that PD-0332991 
monotherapy and combination therapy significantly impaired 
liver colonisation in the RB-high setting (Figure 4A-E), delaying 
disease progression in a metastatic PDA model (Figure 5). 
Of note, CDK4/6i may potentially be a beneficial second-
line therapy, following progression on GEM/nab-Paclitaxel 
in RB-high PDA, as our in vivo findings suggest (Figure 5B). 
Given the high rate of chemotherapeutic resistance in advanced 
patients with PDA treated with these chemotherapies and their 
subsequent extremely poor outcome, pending further preclinical 
study, CDK4/6i-based approaches may potentially be a viable 
second-line treatment for specific subtypes of advanced PDA.
CDK4/6 inhibition modulated ECM organisation in vitro and 
in vivo (Figures 2,5), with in vivo responses to PD-0332991-
based therapy associated with decreased expression of α-SMA, 
a marker of activated PSCs and stromal activation. As our in 
vitro findings suggest that the effects on ECM are independent 
of the antiproliferative activity of PD-0332991, it is plausible 
to hypothesise that changes in ECM mechanics induced by 
PD-0332991 may directly disrupt PSC activation, the subsequent 
tumour cell–PSC crosstalk and ultimately further improve ther-
apeutic sensitivity. Indeed, recent work has shown that matrix 
stiffness and organisation can directly regulate differentiation 
and migration of PSCs.52
PD-0332991 and GEM strongly synergised irrespective of 
p16 or p53 status (eg, whether pancreatic tumour harboured 
an inactivating TP53 mutation (C124*; PDX-26), mutation 
contributing to partial rescue (V173M; PDX-03) or higher than 
wild-type p53 activity (G245S; PDX-05).53 CDK4/CDK6 ampli-
fication or overexpression has been associated with in vitro 
CDK4/6i resistance,47 although CDK4-amplified liposarcomas 
are sensitive to PD-0332991.54 Interestingly, the CDK6-ampli-
fied PDX-26 and matched PDCL responded to PD-0332991-
based treatment, suggesting that in PDA CDK6 amplification in 
the context of functional RB does not preclude effective CDK4 
pathway inhibition. Although CDK6 is strongly functionally 
linked to CDK4, this enzyme may exert other kinase-indepen-
dent functions in regulation of angiogenesis and/or cell differen-
tiation,55 representing a potentially separate thus far unexamined 
role for CDK6 inhibition in PDA therapy.
Several smaller studies have investigated the prognostic role of 
RB in PDA, with inconsistent findings.56 Here, RB protein was 
highly expressed in a significant proportion of PDA (65%, APGI/
ICGC; 43%, NSWPCN; 67%, metastatic cohort), suggesting that 
this could be a viable therapeutic target for tailored CDK4/6i-
based treatments that act on this signalling network. Moreover, 
the observed concordance in RB levels in the small set of avail-
able matched primary and metastatic tissue lends hope that 
metastases may still be co-targeted with this type of therapy. Loss 
of RB protein was associated with poor patient outcome, with 
RB an independent prognostic factor for DSS in two sizeable 
independent PDA cohorts (table 1). RB immunohistochemistry 
was a clean nuclear stain without considerable background. In 
our hands, it appeared comparable with estrogen receptor (ER) 
staining in terms of interpretation of intensity within processed 
material. Pending further validation, the use of a tissue-based 
assay for RB expression could be adapted for clinical applica-
tion in diagnostics to, combined with other markers, help iden-
tify those with poorest prognoses and also potentially identify a 
cohort of patients to trial CDK4/6i.
In conclusion, we provide preclinical proof-of-concept 
for the efficacy of a personalised treatment strategy using 
CDK4/6i to treat RB-high PDA. We reveal key mechanisms 
whereby CDK4-targeting therapy may regulate multiple 
cellular processes and environmental cues within the primary 
tumour, secondary site and during CTC transit, which collec-
tively govern pancreatic cancer progression. We hope that with 
two non-biomarker-driven phase I/II trials of PD-0332991 in 
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pancreatic cancer underway (NCT02501902, NCT03065062), 
these findings may have complementary and potentially signifi-
cant therapeutic implications for the personalised treatment of 
PDA in future.
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